Ascendis Pharma A/S Ordinary Share (ASND) is a publicly traded Healthcare sector company. As of October 26, 2026, ASND trades at $244.00 with a market cap of $16.01B and a P/E ratio of 0.00. ASND moved +0.62% today. Year to date, ASND is +14.13%; over the trailing twelve months it is +21.07%. Its 52-week range spans $124.06 to $282.15. Analyst consensus is strong buy with an average price target of $315.41. Rallies surfaces ASND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ascendis Pharma's TransCon CNP wins positive CHMP opinion for childhood achondroplasia: The CHMP recommended EU authorization of Ascendis Pharma’s once-weekly TransCon CNP for children aged two or older with achondroplasia and open epiphyses. A final European Commission decision is expected in the fourth quarter of 2026; if authorized, the first EU launch is planned in Germany in the first quarter of 2027 under the YUVIWEL brand.
| Metric | Value |
|---|---|
| Price | $244.00 |
| Market Cap | $16.01B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $282.15 |
| 52-Week Low | $124.06 |
| Volume | 119.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
19 analysts cover ASND: 0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $315.41.